GET DAILY SIGNALSLifeStance Health (LFST): Analyst Targets Suggest a Path to $15.50 and +16% Upside
Key Takeaways
- The central $15.50 target is the average of the verified analyst price targets that sit above the current market price, not a published consensus figure.
- At a latest close near $13.37, reaching $15.50 would require a roughly 16% advance from the LFST stock price.
- Across eight current targets from named firms, the range runs from $13 to $18; the overall mean of all eight is about $14.60, just under the 10% threshold used here.
- The strongest supports are accelerating outpatient mental health demand, roughly 26% second-quarter revenue growth, a return to profitability, raised guidance, and a $100 million buyback.
- The biggest risks are an elevated valuation, a sharp recent run-up, clinician labor costs, and insurance-reimbursement dynamics.
- For more detail on Major News, Today's Price Move, the Forecast, and Earnings, explore these dedicated pages.
- Interested readers can also browse Trending AI Robots for automated market-scanning tools.
Analyst Price Targets for LFST
LifeStance Health Group, Inc. (LFST) is a Nasdaq-listed provider of outpatient mental health services, offering virtual and in-person care to children, adolescents, and adults. As a stock with active sell-side coverage, its price outlook is best framed through the individual analyst price targets currently on record.
Recent targets from named firms include BTIG ($18, Buy, Aug. 19, 2026), Canaccord Genuity ($15, Buy), KeyBanc ($15, Buy/Overweight), Jefferies ($15, Buy), Barclays ($15, Overweight), J.P. Morgan ($13, Neutral), Morgan Stanley ($13, Overweight), and BMO Capital ($13, Outperform). That produces a range of $13 to $18, with the most cautious views clustered near $13 and the most bullish view at $18.
The arithmetic mean of all eight valid targets is about $14.60, which is only modestly above the recent price and falls short of the 10% minimum-distance threshold applied in this analysis. Because five of the eight targets sit above the current price ($15, $15, $15, $15, and $18), the central target here is their average, approximately $15.60, rounded to a clean $15.50. This central target reflects the average of the above-price analyst targets, not the overall mean of all targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent close near $13.37, LFST trades near the upper end of a 52-week range that began near $4.77, meaning the shares have roughly tripled from their lows. Reaching $15.50 implies about a 16% upside, a substantial but not extreme move for a high-growth healthcare name.
The path is supported by fundamentals: the company reported roughly 26% revenue growth in its most recent quarter, returned to profitability, raised full-year guidance, and authorized a $100 million share repurchase. Because the stock has already re-rated sharply higher, further progress toward $15.50 would likely depend on sustained margin expansion and continued top-line momentum rather than valuation multiple expansion alone.
Factors That Could Support a Move Toward $15.50
Several verified factors could support a move toward the $15.50 area. Demand for behavioral health services remains structurally strong, and LifeStance's clinician recruitment and utilization have underpinned revenue growth. The return to profitability and raised guidance give analysts a firmer base for their estimates. A string of upward price-target revisions from KeyBanc, Barclays, Jefferies, Canaccord, and BTIG signals improving confidence, while the buyback authorization adds a source of demand for shares.
Risks That Could Keep the Target Out of Reach
The principal risk is valuation. After a dramatic run-up, LFST carries a stretched trailing earnings multiple because profitability is still new and thin. Clinician compensation and recruiting costs can pressure margins, while changes in commercial insurance reimbursement or telehealth regulation could weigh on growth. The wide $13-to-$18 analyst range itself reflects genuine disagreement about how much of the improved outlook is already priced in, and a disappointing quarterly report could easily test the lower end of that range.
Technical Levels to Watch
The shares have broken well above their prior multi-quarter base and now trade near recent highs. Round-number zones carry psychological weight: $13 has functioned as a contested level where several cautious analyst targets cluster, while $15 represents a clustered objective for four firms and a natural resistance level on the way toward BTIG's $18 high estimate. A failure to hold near the prior highs could shift attention back toward the $12-to-$13 band.
Time Horizon and Key Items to Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ. The most important near-term items are the next quarterly earnings release, scheduled for early November 2026, along with updated revenue and margin guidance, commentary on clinician capacity, any further analyst target revisions, and developments in mental-health reimbursement policy. From what I see, these catalysts will likely determine whether momentum holds.
Exploring AI Tools in My Research
Tickeron's AI Daily Buy/Sell Signals have become a regular part of how I monitor names like this. The platform uses artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market shifts. It helps me quickly spot changes without replacing my own fundamental work.
Final Assessment
Whether LFST reaches $15.50 depends on continued execution against a backdrop of strong demand and a richer valuation. The target, an average of the five analyst price targets above the current price, requires roughly a 16% move. Accelerating revenue growth, profitability, raised guidance, and a buyback support the case, while a stretched valuation, a steep prior rally, and reimbursement and labor-cost risks argue for caution. The $13-to-$18 analyst spread shows genuine uncertainty, making the upcoming earnings report and any further target revisions the key signals to watch. In my view, the setup merits close attention but calls for measured position sizing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFST in upward trend: price rose above 50-day moving average on October 22, 2026
LFST moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LFST as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for LFST just turned positive on October 22, 2026. Looking at past instances where LFST's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for LFST crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFST advanced for three days, in 226 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 179 of 246 cases where LFST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for LFST moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 29 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
LFST broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LFST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.441) is normal, around the industry mean (204.016). P/E Ratio (95.500) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.094) among similar stocks. P/S Ratio (3.182) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement